The presentation was made available to investors and stakeholders ahead of the Investor Conference Call scheduled to discuss the company's financial and operational performance.

Financial Performance Highlights

FY2026 Performance:

  • Revenue from Operations: ₹73.13 crore
  • EBITDA: ₹12.72 crore
  • EBITDA Margin: 17.39%
  • Profit Before Tax: ₹12.22 crore (26.24% growth YoY)
  • Net Profit (PAT): ₹9.03 crore (24.72% growth YoY)
  • EPS: ₹5.44

Three-Year Financial Track Record (FY24-FY26):

  • Revenue Growth (3 Years Compounded): 26%
  • PAT Growth (3 Years Compounded): 15%
  • Average ROCE (3 Years): 25.74%
  • Average ROE (3 Years): 19.39%
  • Debt Position: Almost Debt Free

Year-over-Year Financial Comparison:

| Particulars | FY24 | FY25 | FY26 |

| Revenue from Operations | ₹40.02 crore | ₹50.66 crore | ₹73.13 crore |

| EBITDA | ₹8.58 crore | ₹10.07 crore | ₹12.72 crore |

| EBITDA Margin | 21.44% | 19.88% | 17.39% |

| Net Profit (PAT) | ₹6.20 crore | ₹7.24 crore | ₹9.03 crore |

| Net Margin | 15.49% | 14.29% | 12.35% |

| ROCE | 32.39% | 24.48% | 20.35% |

| ROE | 24.61% | 18.43% | 15.13% |

Balance Sheet Changes (Mar'25 to Mar'26):

  • Equity Capital: Increased from ₹11.56 crore to ₹16.61 crore (43.69% growth)
  • Reserves: Increased from ₹31.16 crore to ₹60.02 crore (92.62% growth)
  • Borrowings: Reduced from ₹1.04 crore to ₹0.80 crore
  • Total Liabilities: Increased from ₹48.34 crore to ₹84.23 crore (74.24% growth)
  • Fixed Assets: Increased from ₹5.96 crore to ₹7.14 crore (19.80% growth)
  • Other Assets: Increased from ₹41.70 crore to ₹76.41 crore (83.24% growth)

Strategic Initiatives and Expansion Plans

Manufacturing Expansion:

  • The company has acquired land near Himmatnagar, Gujarat for development of its second manufacturing facility
  • The upcoming unit is expected to significantly enhance production capacity

Product Development:

  • Company is preparing to launch a new range of high-value nutraceutical and herbal healthcare products
  • Ongoing investments in advanced formulations and research-driven healthcare solutions
  • Focus on modern nutraceutical technologies to meet evolving global healthcare demands

Vision 2030:

  • Target to scale operations substantially through capacity expansion, innovation-driven product launches, and global market penetration
  • Long-term growth vision under the theme "Innovate | Expand | Excel"

Company Overview

Shelter Pharma Limited is positioned as "India's Emerging Human and Veterinary Healthcare Company" with over six decades of experience since establishment in 1965. The company operates in both human and veterinary healthcare segments with comprehensive portfolios of Ayurvedic, herbal, and healthcare solutions.

Leadership

  • Mustaqim Sabugar: Promoter, Managing Director with 30+ years of experience in pharma sector
  • Shakeel Sabugar: Promoter & Whole Time Director

Investor Relations Contacts

  • Company Secretary: Aarefa Kutub Kapasi (cs@shelter.co.in)
  • Investor Relations Advisors: FINANCIAL MINDSS (A JaiBharti Group Co.)
  • Contact: CA CS LLB Praveen Ranjan (+91 9967487950, ir@financialmindss.com)

Disclaimer Notes

The presentation contains forward-looking statements based on current expectations, assumptions, and projections, with the company noting that actual results may differ materially due to various risks and uncertainties. The company assumes no obligation to update any forward-looking statements.